Home   Logon   Mobile Site   Research and Commentary   About Us   Call 1.800.621.1675 or Email Us       Follow Us: 

Search by Ticker, Keyword or CUSIP       
Blog Home
Jeff Margolin
Closed-End Fund Analyst
Click for Bio

Follow Jeff on LinkedIn
Ryan Issakainen
ETF Strategist
Click for Bio

Follow Ryan on LinkedIn

  Seeking Alpha with Biotechnology ETFs
Posted Under: ETFs
2014 is shaping up to be another strong year for the biotechnology industry and associated exchange-traded funds (ETFs). After declining nearly 20% from February to April, the NYSE Arca Biotechnology Index rebounded to new highs during the month of August, boosting year-to-date returns to 34.6% (through 8/31/14). As in years past, the industry's news flow contained a number of important announcements that significantly impacted near term returns for biotechnology stocks. While such stories have a tendency to frame investors' conceptions of biotechnology ETFs in terms of short-term, tactical trading opportunities, a compelling case can also be made for longer-term, strategic allocations to the biotechnology industry.
In many respects, biotechnology is unlike other industries. To a large extent, future earnings for these companies depend on innovation that pushes the boundaries of scientific understanding. On the one hand, tremendous resources can be expended on ventures that ultimately provide little or no payoff; on the other, scientific breakthroughs may create blockbuster revenue streams. Moreover, circumstances that are largely beyond the control of biotechnology companies, such as decisions made by regulators, can make or break a project.
Click here to continue reading.
Posted on Thursday, September 11, 2014 @ 1:45 PM • Post Link Share: 
Print this post Printer Friendly

These posts were prepared by First Trust Advisors L.P., and reflect the current opinion of the authors. They are based upon sources and data believed to be accurate and reliable. Opinions and forward looking statements expressed are subject to change without notice. This information does not constitute a solicitation or an offer to buy or sell any security.
Municipal Market Update - 2nd Quarter 2014
Senior Loan & High Yield Review - 2nd Quarter 2014
The Other Discount Advantage
Municipal Closed-End Funds: MNCEFT Closes Above 1600; Silent Rally Continues
Commodity ETFs and the Business Cycle
Year-To-Date Performance of Municipal Closed-End Funds Shows the Importance of Balance
Mid-Quarter Update: Good Start to 2014 for Many Categories of CEF Marketplace; Still Compelling Values Available
Preparing for the Unexpected with Commodity Futures ETFs
The Power of Closed-end Fund Distributions
Following Solid December, Municipal CEFs off to Good Start in 2014
Skip Navigation Links.
Search by Topic
Skip Navigation Links.

The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
First Trust Portfolios L.P.  Member SIPC and FINRA. (Form CRS)   •  First Trust Advisors L.P. (Form CRS)
Home |  Important Legal Information |  Privacy Policy |  California Privacy Policy |  Business Continuity Plan |  FINRA BrokerCheck
Copyright © 2020 All rights reserved.